Biomea Fusion, INC Form 4 insider transactions

Director Julianne Averill was granted 173,711 stock options with an exercise price of $1.15 as part of her compensation package.

Biomea Fusion's President and COO, Rainer M. Erdtmann, acquired 30,000 shares of common stock, signaling strong insider confidence.

Biomea Fusion's Interim CEO, Michael J.M. Hitchcock, acquired 100,000 shares of common stock at a weighted average price of $0.9918 per share.

Biomea Fusion's President and COO, Rainer M. Erdtmann, increased his direct and indirect holdings of common stock through recent purchases.

Biomea Fusion's Interim CEO and Director, Michael J.M. Hitchcock, was granted 916,434 stock options with an exercise price of $1.53, vesting quarterly over four years.

Biomea Fusion's President and COO, Rainer M. Erdtmann, reported gifting shares of common stock to family members and updating his beneficial ownership.

Bihua Chen and affiliated Cormorant funds will no longer file SEC Form 4 or 5 for Biomea Fusion, Inc. following Ms. Chen's resignation as director and their collective beneficial ownership falling below the 10% threshold.

Biomea Fusion, Inc. Director Julianne Averill was granted 241,177 stock options with an exercise price of $1.82, vesting monthly over three years.

Biomea Fusion, Inc. Director Elizabeth Faust was granted 91,970 stock options with an exercise price of $2.50, vesting over the next year.

Biomea Fusion, Inc. Director Eric Aguiar was granted 91,970 stock options with an exercise price of $2.5, vesting over one year or prior to the next annual meeting.

Biomea Fusion, Inc. Director Sumita Ray was granted 91,970 stock options with an exercise price of $2.5, vesting upon specific conditions.

A recent SEC Form 4 filing reveals that Bihua Chen, a director and 10% owner of Biomea Fusion, Inc., acquired 91,970 new stock options with an exercise price of $2.50.

Michael J.M. Hitchcock, Interim CEO of Biomea Fusion, Inc., was granted 350,000 stock options on March 26, 2025, according to a Form 4 filing with the SEC.

Biomea Fusion's Chief Financial Officer, Franco Valle, acquired 495 shares of common stock through the company's Employee Stock Purchase Plan at a price of $6.154 per share.

Director Michael J.M. Hitchcock of Biomea Fusion, Inc., reports purchasing 10,000 shares of common stock and disposing of 15,000 shares on September 30, 2024.

Director Bihua Chen reports acquisition of stock options and beneficial ownership of Biomea Fusion, Inc. shares through Cormorant Asset Management funds.

Director Sumita Ray acquired stock options for 51,025 shares of Biomea Fusion, Inc. at an exercise price of $4.63 on June 12, 2024.

Director Elizabeth Faust reports the acquisition of stock options in Biomea Fusion, Inc.

Director Michael Hitchcock acquired stock options in Biomea Fusion, Inc. on June 12, 2024.

Director Eric Aguiar acquired stock options in Biomea Fusion, Inc. on June 12, 2024.

Franco Valle, CFO of Biomea Fusion, reports acquiring and disposing of company stock through an employee stock purchase plan and open market purchases.

Juan Pablo Frias, Chief Medical Officer of Biomea Fusion, Inc., acquired 349 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) on May 31, 2024.